

1 **Association of attrition with mortality:**

2 **Findings from 11 waves over three decades of the Whitehall II study**

3

4 Mifuyu Akasaki¹, Mika Kivimäki², Andrew Steptoe¹, Owen Nicholas^{3*}, Martin J Shipley^{2*}

5 *Joint senior authors

6

7 Words 2981

8 Figures 3

9 Tables 3

10

11 1. Department of Behavioural Science and Health, University College London, 1-19 Torrington Place,
12 London WC1E 6BT United Kingdom

13

14 2. Department of Epidemiology and Public Health, University College London, 1-19 Torrington Place,
15 London WC1E 6BT United Kingdom

16

17 3. Department of Statistical Science, University College London, 1-19 Torrington Place, London
18 WC1E 6BT United Kingdom

19

20

21 Correspondence to Mifuyu Akasaki, Department of Behavioural Science and Health, University
22 College London, 1-19 Torrington Place, London WC1E 6BT United Kingdom

23

24 **ABSTRACT**

25 **Background**

26 Attrition, the loss of participants as a study progresses, is a considerable challenge in longitudinal
27 studies. This study examined whether two forms of attrition, “*withdrawal*” (formal discontinued
28 participation) and “*non-response*” (non-response among participants continuing in the study) have
29 different associations with mortality, and whether these associations differed across time in a multi-
30 wave longitudinal study.

31 **Methods**

32 Participants were 10 012 civil servants who participated at the baseline of the Whitehall II cohort study
33 with 11 data waves over average follow-up of 28 years. We performed competing-risks analyses to
34 estimate sub-distribution hazard ratios and 95% confidence intervals, and likelihood ratio tests to
35 examine whether hazards differed between the two forms of attrition. We then applied linear regression
36 to examine any trend of hazards against time.

37 **Results**

38 Attrition rate at data collections ranged between 13% and 34%. There were 495 deaths recorded from
39 cardiovascular disease and 1367 deaths from other causes. Study participants lost due to attrition had
40 1.55 (95% confidence interval 1.26 to 1.89) and 1.56 (1.39 to 1.76) times higher hazard of
41 cardiovascular and non-cardiovascular mortality than responders respectively. Hazards for withdrawal
42 and non-response did not differ for either cardiovascular (p-value = 0.28) or non-cardiovascular
43 mortality (p-value = 0.38). There was no linear trend in hazards over the 11 waves (cardiovascular
44 mortality p-value = 0.11, non-cardiovascular mortality p-value = 0.61).

45 **Conclusion**

46 Attrition can be a problem in longitudinal studies resulting in selection bias. Researchers should
47 examine the possibility of selection bias and consider applying statistical approaches that minimise
48 this bias.

49

50 **Key words**

51 Attrition; withdrawal; non-response; longitudinal study; selection bias; collider bias

52

53 **Summary Box**

54

What is already known on this topic

55

- Non-participation at baseline is known to be associated with increased risk of all-cause mortality.

56

- However, it is uncertain whether this finding is generalisable to attrition during follow-up in multi-wave longitudinal studies.

57

- Also, it is unknown whether attrition predicts cardiovascular mortality, and whether the association differs between two forms of attrition; non-response and withdrawal.

58

What this study adds

59

- Participants lost due to attrition, no matter when attrition occurs in the study, have approximately 1.5 times higher mortality within three to five years than responders. Attrition, therefore, does have the potential to cause bias in follow-up studies.

60

61

- We recommend that researchers report characteristics of those excluded from the study to allow readers to evaluate the validity of findings, and consider applying statistical methodologies in analyses to minimise selection bias due to attrition.

62

63

64 **Introduction**

65 Many long-term cohort studies are affected by gradual attrition due to withdrawal and non-response
66 (1). One challenge is to ensure that inferences drawn are applicable to the members of the study
67 population; internal validity (2, 3). If some study participants do not respond and they have
68 systematically different characteristics from those who do, then estimated effects among the
69 responders may not pertain to the original study population (4, 5). In this situation, estimation may be
70 biased, thus undermining external validity or generalisability (2, 3). In addition, ensuring internal and
71 external validity are important challenges for researchers as response rates in studies have generally
72 declined over the past four decades, possibly because of increased burden on participants (e.g. increase
73 in the number of studies, more extensive and time-consuming questionnaires, biological sampling, the
74 requirements of participants' consent) (6, 7).

75 Studies have investigated characteristics of non-responders to understand predictors of non-response,
76 and potential for bias in results. For instance, those who drop out from studies are more likely to be
77 men (8-10), be young or old people (11, 12), be single (8, 13), be in a lower employment grade (14,
78 15), have adverse smoking or alcohol drinking habits (16, 17), have greater cognitive impairment (10,
79 18), and have worse health (14, 19). Analysis of the Whitehall II study, a large multi-wave cohort
80 study, has shown differences in characteristics of participants when distinguishing between response,
81 non-response, or withdrawal - the three categories of "response status" - of a participant (8).

82 Withdrawers from the study were more likely to have adverse mental health, while non-responders
83 were less likely to have long-standing illnesses (8). Not only is it important for this study, and others,
84 to recognise and compensate for those at higher risk being under-represented in participants (20), but
85 also it is important to address whether there are clear differences in risk by category of attrition, and if
86 so why.

87 Population-based studies linked with electronic health records suggest that attrition is associated with
88 an approximate doubling of the risk of mortality (16, 21, 22). To date, most relevant studies have
89 employed response status at a single time point (i.e. baseline), with no distinction between withdrawals
90 and non-responders, or have used patterns of response status over time (21, 23). It is unclear whether

91 the association of attrition with higher mortality applies only to non-responders at baseline, or whether
92 the association persists and applies to all waves. If there were a trend in the risk of mortality in
93 responders compared to the risk in those lost to attrition even after adjustment for measured factors
94 such as age, it would be a sign that differences in unmeasured risk factors between responders and
95 those lost to attrition change wave to wave; hence a sign that sources of bias change wave to wave
96 (24). Some studies have examined trends in mortality over time by baseline response status, but failed
97 to consider response status at follow-up (22, 25). Furthermore, it is unknown whether attrition is
98 associated with increased mortality in CVD, a major cause of death.

99 Accordingly, this study aims to (i) examine the extent to which response status at each wave is
100 associated with cardiovascular and non-cardiovascular mortality up to the following wave; (ii)
101 investigate whether the hazard of mortality differs between two forms of attrition: withdrawal, and
102 non-response; and (iii) assess whether there is a trend across waves in the association between attrition
103 and mortality.

104

105 **Methods**

106 **Study population**

107 The Whitehall II study was established in 1985 to determine the factors which contribute to social
108 inequalities in health. There were 10 308 participants (men 6895; women 3413, aged 33-55) at entry to
109 the study (wave 1) who were non-industrial civil servants from 20 Civil Service Departments in
110 London. The study has had twelve waves of data collection up to 2016. The response rate in each wave
111 has remained over 65% across all waves separated by three years on average. We included 10 012
112 participants who responded at baseline and who have no missing values in covariates and mortality
113 (Figure 1).

114 **Variables**

115 *Response status*

116 The Whitehall II study has conducted both self-administered questionnaires and medical examinations
117 at odd-numbered waves, and self-administered questionnaires only at even-numbered waves, In our
118 analysis, for each study participant at each wave, “response” is when the participant either completes
119 the self-administered questionnaire or attends the medical examinations at a wave. “Withdrawal” is
120 when the participant officially informs the study research team that they wish to permanently leave the
121 study, and “non-response” is when the participant (who has not formally withdrawn from the study)
122 does not respond at a certain wave. Participants who have withdrawn from the study are not contacted
123 again at future waves whereas non-responders are re-contacted and could participate at later waves.
124 Non-response is not due to mortality. We term either withdrawal or non-response as “attrition”, and
125 “response status” as comprising response and attrition. Prior to wave 4 it is not possible to distinguish
126 withdrawal from non-response due to the way how the data were collected. We therefore conducted
127 two analyses. In analysis 1, we used all waves from wave 1 in terms of attrition (i.e. withdrawal or
128 non-response combined) and in Analysis 2 we analysed data from wave 4 onwards, using all three
129 categories of response status (i.e. withdrawal, non-response, response). Reasons for withdrawal and
130 non-response were not available.

131 *Mortality*

132 Cardiovascular disease (CVD) and non-CVD mortality were tracked by the National Health Services
133 (NHS) central registry. CVD mortality includes coronary heart disease, angina, myocardial infarction
134 and stroke. Mortality was tracked from wave 1 to August 2017 in 10 292 participants (99.8%), with
135 mean follow-up of 28.7 years (standard deviation: 5.1 years). We identified CVD mortality based on
136 International Classification of Disease (ICD)-9 (codes 390-459) and 10 (codes I00 - I99). Non-CVD
137 mortality includes cancer (ICD-9: 140-239; 10: C00-C97), respiratory mortality (ICD-9: 460-519; 10:
138 J00-J99) and any other cause not classified as CVD mortality.

139 *Covariates*

140 We adjusted for factors related to sociodemographic characteristics, health risk behaviours, and
141 general health status to examine whether these could explain the associations between response status

142 and mortality. Covariates were available only when response status was “response” and therefore
143 present for all participants only at wave 1. We measured covariates using standard questionnaire
144 measures.

145 *Sociodemographic characteristics*

146 Participants’ sex, age in years, ethnicity (white vs. non-white), marital status (married/cohabiting,
147 single, divorced/widowed) and employment grade are all associated with health (26) and were taken
148 from the first wave of the study. Information on sex, age, and employment grade at wave 1 was known
149 for all participants. Missing values in ethnicity and marital status were replaced, where known, with
150 responses from the wave 5 and wave 2 questionnaire respectively. Employment grade was categorised
151 as “administrative” (high grade), “professional/executive” (intermediate grade), and “clerical/support”
152 (low grade).

153 *Health risk behaviours*

154 Health behaviours were taken from participants’ questionnaire responses at wave 1 of the study.
155 Smoking habit (never-smoker, ex-smoker, and current-smoker), alcohol drinking (<14 units per week
156 and ≥ 14 and over units per week), and leisure-time physical activity (high, intermediate, low) were
157 included. Physical activity was assessed based on answers to questions about the frequency and
158 duration of participation in moderately energetic (e.g. dancing, cycling, leisurely swimming), and
159 vigorous physical activity (e.g. running, hard swimming, playing squash). Missing values were
160 replaced with those from the waves 2 and 3. The cut-off points for alcohol consumption and physical
161 activity were determined in line with the NHS guideline (27).

162 *General health status*

163 The 36-item Short Form Health Survey (SF-36) physical – Physical Component Score (PCS) - and
164 mental – Mental Component Score (MCS) - scores were included. PCS is derived from; general health
165 perceptions (5 items), physical functioning (10 items), role limitations due to physical functioning (4
166 items), bodily pain (2 items). MCS is derived from; vitality (4 items), general mental health (5 items),
167 role limitations due to emotional problems (3 items), and social functioning (2 items). Higher scores

168 represent better health. PCS and MCS are not available prior to wave 3 and were therefore omitted
169 from Analysis 1. Analysis 2 treated PCS and MCS from the previous wave as covariates. Missing PCS
170 and MCS values were replaced using the last known measurement carried forward. We categorised
171 PCS and MCS using wave- and sex-specific quartiles.

172 **Statistical methods**

173 We calculated participants' response rate across all waves of the study as the number of waves
174 responded divided by the number of waves that they could have responded to while still alive (28). Mean
175 response rates and 95% confidence intervals (CIs) by levels of each covariate were calculated.

176 We used competing-risks analysis to assess the association of subsequent mortality with the time scale
177 being study wave, with attrition status (analysis 1) or response status (analysis 2) at each wave as the
178 exposure. The sub-distribution hazard ratios (SHRs) and 95% CIs of CVD mortality were estimated
179 using non-CVD mortality as a competing risk. Similarly, those of non-CVD mortality were estimated
180 with CVD mortality as a competing risk. We included interaction terms between attrition/response
181 status and sex, age, and employment grade, to assess whether these factors modified associations
182 between attrition/response status and mortality. We also investigated whether SHRs showed evidence
183 of trend across waves by regressing point estimates of SHRs against wave. We conducted two analyses
184 as follows (Figure 1).

185 *Analysis 1:* We analysed 10 012 participants, initially for the association of attrition status with CVD
186 and non-CVD mortality from wave 1 up to August 2017, adjusted for sex and age, and finally
187 additionally adjusting for marital status, ethnicity, employment grade, smoking, alcohol drinking, and
188 physical activity.

189 *Analysis 2:* In 8791 participants we analysed the association of response status with CVD and non-
190 CVD mortality, from wave 4 up to August 2017, adjusting as in analysis 1 with the addition of PCS
191 and MCS from the previous wave as time-varying variables. In this analysis, we included participants
192 who had responses in both PCS and MCS from at least one wave between wave 3 and wave 11.

193 Likelihood ratio tests were used to examine whether the estimated risks of mortality differ across the
194 two forms of attrition by comparing models of attrition status with models of response status.

195 We conducted sensitivity analyses by repeating analysis 1 using person-years, rather than wave, as the
196 time scale in the same models as used in the main analysis.

197 We used the Stata SE version 15.1 for all analyses.

198

199 **Results**

200 The total number of participants recruited into the Whitehall II study at wave 1 was 10 308, and their
201 response status at each wave is given in Table 1. The attrition rate was between one fifth and one third
202 of eligible study population (those who had not died) at each wave except at waves 3 and 4 when
203 efforts were made to raise participation. The proportion of deaths attributable to CVD rose, then fell,
204 as research participants aged. In analysis 1, we included 10 012 participants, who had no missing
205 values in covariates, CVD, and non-CVD mortality (men; 67.4%). Table 2 shows the participants'
206 response rates (the proportion of waves attended) according to the characteristics of study population.
207 Response rates were higher in men (81.9%) than women (74.0%), and showed a trend across
208 employment grade, being highest in the highest grade (86.1%) and lowest in the lowest grade (66.2%).

209 Table 3 shows the association between attrition status and CVD and non-CVD mortality. There were
210 495 deaths recorded from CVD and 1367 deaths from non-CVD. Compared to responders, participants
211 with attrition had 1.55 (95% CI 1.26 to 1.89) times the hazard of CVD mortality after adjustment for
212 sex, age, ethnicity, marital status, employment grade, smoking habit, alcohol drinking, and physical
213 activity. For non-CVD mortality, the hazard ratio was 1.56 (1.39 to 1.76). The association between
214 attrition and mortality was not modified by sex, age, or employment grade. Table S1 in the online
215 supplementary file shows the SHRs and 95% CIs for the association between attrition and CVD and
216 non-CVD mortality from each wave to the following wave, on average a period of three years. There
217 was no evidence of trend in point estimates of SHRs across the waves for either CVD mortality (p-
218 value = 0.11) or for non-CVD mortality (p-value = 0.61). Sensitivity analyses using person-years,

219 rather than wave, showed the same pattern of results, but with all the SHRs slightly reduced (Table S2,
220 online supplementary material).

221 From wave 4 onwards, attrition could be partitioned into non-responders and those who had
222 completely withdrawn from the study. Among 8791 participants in analysis 2, there were 353 deaths
223 recorded from CVD and 1056 deaths from other causes. Figure 2 shows the cumulative incidence
224 function (CIF) for CVD and non-CVD mortality from wave 4 for each response status. For CVD
225 mortality, the curves of CIF between non-response and withdrawal diverged, whilst for non-CVD
226 mortality those between non-response and withdrawal were almost parallel. The association of
227 response status with mortality is shown graphically in the figure 3, and further details of the results are
228 given in Tables S3, S4, and S5 in the online supplementary material. Likelihood ratio tests showed no
229 evidence that the differentiation of two types of attrition improved the models for either CVD (p-value
230 = 0.28) or non-CVD mortality (p-value = 0.38).

231

232 **Discussion**

233 The principal findings are that, compared to responders, attrition after baseline is associated with
234 approximately 1.5 times higher hazard of mortality for both CVD and non-CVD mortality after
235 adjustment for covariates. There is no difference in the hazard of either CVD or non-CVD mortality
236 between withdrawal and non-response. In addition, the association of attrition with mortality does not
237 vary across waves.

238 Our findings show a slightly weaker association than previous studies, which have reported a doubling
239 of the hazard of mortality in those with attrition compared to responders (16, 21, 22). This may be
240 because previous studies categorised response status retrospectively from deaths as an end point, while
241 we used prospectively measured response status; or because the majority used response status at
242 baseline only, not during follow-up. It may be explained by the previous findings that non-responders
243 at baseline had a remarkably higher hazard of mortality than participants in longitudinal studies (16,
244 21, 22, 25). We found no differences in the hazard between withdrawal and non-response, our null

245 hypothesis. A possible explanation is that, among those lost due to attrition, the two distributions of
246 reasons for attrition, between withdrawals and non-responders, do not differ across the waves. The
247 associations of response status with CVD mortality were attenuated with adjustment for
248 sociodemographic factors and health risk behaviours, consistent with the previous studies (8-18, 29-
249 31). Morbidity is also one of the potential predictors of attrition. Some (14, 19, 32), but not all (8) of
250 the literature has documented that those who have illness are more likely to be lost to follow-up. To
251 examine this association, we included physical and mental health status using SF-36 from the previous
252 wave in the model. However, it did not attenuate the association, possibly because it may depend on
253 the severity of illness, whether illness is acute or chronic, or the existence of psychological illness,
254 rather than general health status.

255 The association between response status and subsequent mortality is not causal; however, as our study
256 shows, response status may predict mortality in later waves. This implies that internal and external
257 validity of studies may be affected in certain circumstances (4, 33, 34). For example, selection can lead
258 to collider bias (a bias occurring when two variables independently affect a third variable, and that
259 third variable is conditioned upon), which can bias estimations (4). Complete case analysis would not
260 be problematic if it can be assumed that missingness occurs completely at random (34). This is,
261 however, a strong assumption. When some data are available for those subsequently lost due to
262 attrition, multiple imputation or inverse probability weighting can be used to reduce, or even remove,
263 the possible selection bias. Some other alternative approaches have also been discussed (34-37).

264 We hypothesised that differences in hazards between participants and those lost due to attrition would
265 change with time. Our study, however, did not support this hypothesis, which suggests that relative
266 changes of unmeasured risk-factors in responders compared to withdrawers/non-responders were
267 either absent, or not sufficiently large to influence outcomes.

268 Our study has limitations. Due to the way in which the data were collected up to wave 4, we were
269 unable to distinguish withdrawal from non-response in analysis 1. If the magnitude of associations
270 with mortality differed between withdrawal and non-response up to wave 4, our results in the analysis
271 2 might not generalise across all waves of the study. Because of the small number of deaths for each

272 specific cause, we pooled all non-CVD deaths, which may have resulted in a diluted hazard since
273 aetiology certainly differs across diseases. Cognitive impairment, a considerable determinant of the
274 attrition (38), may have a major influence particularly in ageing cohort studies. However, we were
275 unable to examine associations between cognitive function, attrition, and mortality because cognitive
276 function was measured only from wave 5, by which time about three-quarters of the total attrition had
277 already occurred. Although some results from the Whitehall II study could apply to more general
278 populations (39), it would be interesting to repeat this work in a general population cohort to examine
279 whether the association of response status with mortality is also reproducible. Further research on
280 cause-specific mortality, such as subtypes of cancer, is required to estimate the hazard by response
281 status in longitudinal studies.

282 In conclusion, these findings suggest that those who are lost due to attrition, no matter when attrition
283 occurs, have an excess mortality within three to five years. Attrition, therefore, does have the potential
284 to cause bias in follow-up studies. The response rate could be an indicator of selection bias, however
285 not always (4, 33). We therefore recommend that researchers report characteristics of those excluded
286 from the study to allow readers to evaluate the validity of findings, and consider applying statistical
287 methodologies to minimise bias due to attrition.

Table 1. Response status and cumulative death (CVD, all-cause) at each wave

Wave	Period	Participants (responders)	Attrition ^a			Cumulative CVD death (%) ^d	Cumulative all-cause death
			<i>Cumulative Withdrawal (%)^b</i>	<i>Non-response (%)^b</i>	<i>Total (%)^c</i>		
1	1985-1988	10 308	-	-	-	-	-
2	1989-1990	8132		2127 (20.7) ^c	2127 (20.7)	14 (28.6)	49
3	1991-1994	8815		1368 (13.4) ^c	1368 (13.4)	36 (28.8)	125
4	1995-1996	8628	774 (52.4)	712 (47.6)	1486 (14.7)	59 (30.4)	194
5	1997-1999	7870	882 (41.3)	1250 (58.7)	2132 (21.3)	95 (31.0)	306
6	2001	7355	975 (38.7)	1553 (61.3)	2528 (25.6)	132 (31.1)	425
7	2002-2004	6967	1246 (45.2)	1511 (54.8)	2757 (28.4)	176 (30.1)	584
8	2006	7173	1310 (55.5)	1051 (44.5)	2361 (24.8)	226 (29.2)	774
9	2007-2009	6761	1354 (52.2)	1239 (47.8)	2593 (27.7)	271 (28.4)	954
11 ^f	2012-2013	6308	1389 (53.7)	1197 (46.3)	2586 (29.1)	405 (28.6)	1414
12	2015-2016	5632	1433 (49.7)	1448 (50.3)	2881 (33.8)	485 (27.0)	1795
<i>Deaths to August 2017</i>						<i>519 (26.7)</i>	<i>1943</i>

^a Deaths are displayed separately from attrition (non-response or withdrawal)

^b % of each attrition = [withdrawal or non-response / total attrition at each wave] * 100

^c % attrition = [total attrition at each wave / (10308 - cumulative deaths at each wave)] * 100

^d % CVD death = (CVD death / all-cause death) * 100

^e Only pooled attrition is available at waves 2 and 3

^f Wave 10 was a small pilot study of measures to be included at wave 11, and has not been included here

Table 2. Characteristics of study population (n=10 012)

	<i>n (%)</i>	Response rate (95%CI)^a
Sex		
Men	6749 (67.4)	81.9 (81.7-82.2)
Women	3263 (32.6)	74.0 (73.6-74.5)
Age in years		
39 and below	2750 (27.5)	79.9 (79.5-80.4)
40 - 44	2607 (26.0)	80.0 (79.6-80.5)
45 - 49	2031 (20.3)	78.8 (78.2-79.3)
50 and over	2624 (26.2)	78.5 (78.0-79.0)
Ethnicity		
White	8968 (89.6)	80.9 (80.7-81.2)
Non-white	1044 (10.4)	65.8 (64.9-66.7)
Marital status		
Married/cohabit	7435 (74.3)	80.7 (80.4-81.0)
Single	1640 (16.4)	76.3 (75.7-77.0)
Divorced/widowed	937 (9.4)	74.0 (73.1-74.9)
Employment grade		
High	2979 (29.8)	86.1 (85.7-86.4)
Intermediate	4837 (48.3)	81.1 (80.7-81.4)
Low	2196 (21.9)	66.2 (65.5-66.8)
Smoking habit		
Never-smoker	4966 (49.6)	80.7 (80.4-81.1)
Ex-smoker	3225 (32.2)	81.3 (80.9-81.7)
Current smoker	1821 (18.2)	71.8 (71.1-72.4)
Alcohol drinking		
<14 units per week	7338 (73.3)	78.4 (78.2-78.7)
≥14 units per week	2674 (26.7)	81.9 (81.5-82.4)
Physical activity		
High	2175 (21.7)	80.9 (80.4-81.4)
Intermediate	2620 (26.2)	80.9 (80.5-81.4)
Low	5217 (52.1)	77.9 (77.6-78.3)

^a Response rate = [number of waves responded / number of waves that it was possible to attend while still alive]*100

Table 3. Sub-distribution hazard ratios (SHRs) of CVD and Non-CVD mortality from wave 1 to August 2017, by attrition status^a (n=10 012)

Outcome	Attrition status	No. deaths	SHR (95% CI)		
				<i>Sex and Age</i>	<i>Adjusted for All factors^b</i>
CVD mortality		495			
	Response	312		<i>ref.</i>	<i>ref.</i>
	Withdrawal/Non-response	183	1.86	(1.53-2.24)	1.55 (1.26-1.89)
Non-CVD mortality		1367			
	Response	873		<i>ref.</i>	<i>ref.</i>
	Withdrawal/Non-response	494	1.62	(1.45-1.82)	1.56 (1.39-1.76)

^a Attrition status is time dependent and varies at each wave of the study

^b Adjusted for sex, age, ethnicity, marital status, employment grade, smoking habit, alcohol drinking, and physical activity

Figure 1. Flow chart of participants' recruitment

Figure 2. Cumulative incidence function of CVD and Non-CVD mortality by response status (left; CVD mortality, right; non-CVD mortality)

Figure 3. Sub-distribution Hazard Ratios (SHRs)^a and 95% Confidence Intervals (CIs) of CVD and Non-CVD mortality by response status

^a SHRs of *withdrawal/non-response* are based on 10 012 participants (analysis 1), adjusted for sex, age, ethnicity, marital status, employment grade, smoking habit, alcohol drinking, and physical activity. SHRs of *withdrawal* and *non-response* are based on 8791 participants (analysis 2), adjusting as in analysis 1 with the addition of PCS and MCS.

Contributors: MA conceived the initial idea for the paper and elaborated this with all authors; MA and ON designed the study, and MA, ON and MJS undertook statistical analysis. MA, MK, AS, ON, and MJS drafted the article. All authors contributed to the critical revision and the final approval of the version to be published. MA is guarantor. All authors had agreement to be accountable for the accuracy and integrity of the study. The corresponding author affirms that all authors meet authorship criteria recommended in the International Committee of Medical Journal Editors (ICMJE) Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals 2013. The corresponding author attests that all listed authors meet authorship criteria and that no others meeting the criteria have been omitted.

Acknowledgements. We thank all of the participating civil service departments and their welfare, personnel, and establishment officers; the British Occupational Health and Safety Agency; the British Council of Civil Service Unions; all participating civil servants in the Whitehall II study; and all members of the Whitehall II study team. The Whitehall II Study team comprises research scientists, statisticians, study coordinators, nurses, data managers, administrative assistants and data entry staff, who make the study possible.

Funding: The study was supported by the UK Medical Research Council (MRC, K013351; R024227), the US National Institute on Aging (NIA, R56AG056477; R01AG0564779), and the British Heart Foundation (32334). MA is funded by a PhD scholarship from the Foundation for Advanced Studies on International Development (FASID). MK is supported by the MRC (S011676, R024227), NIA (R01AG0564779), NordForsk, Academy of Finland (311492) and Helsinki Institute of Life Science. MJS is partly supported by the British Heart Foundation. The funders did not contribute to the study design, data collection, analysis, interpretation, drafting, nor the decision to publish the study.

Licence for Publication: The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all authors, an exclusive licence (or non exclusive for government employees) on a worldwide basis to the BMJ Publishing Group Ltd to permit this article (if accepted) to be published in JECH and any other BMJ PGL products and sublicences such use and exploit all subsidiary rights, as set out in our licence.

Competing interests: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: no support from any organisation for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work.

Ethical approval: It was not required since the study used secondary data. The Joint University College London/University College London Hospital Committees on the Ethics of Human Research has approved the Whitehall II study.

Transparency statement: MA affirms that the manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as originally planned (and, if relevant, registered) have been explained.

Data sharing: Data of the Whitehall II study are available to the scientific community. Data sharing policy is available at <https://www.ucl.ac.uk/epidemiology-health-care/research/epidemiology-and-public-health/research/whitehall-ii/data-sharing>.

Dissemination plans: The dissemination plan targets a wide audience, including members of the public, patients, health professionals, and academic researchers in the speciality through various channels such as written communication, conferences, and social media.


Reference

1. Rothman KJ, Gallacher JE, Hatch EE. Why representativeness should be avoided. *International journal of epidemiology*. 2013;42(4):1012-4.
2. Rothman KJ, Greenland S, Lash TL. *Modern epidemiology*: Lippincott Williams & Wilkins; 2008.
3. Porta M. *A dictionary of epidemiology*: Oxford university press; 2014.
4. Munafo MR, Tilling K, Taylor AE, Evans DM, Davey Smith G. Collider scope: when selection bias can substantially influence observed associations. *Int J Epidemiol*. 2018;47(1):226-35.
5. Greenland S. Quantifying Biases in Causal Models: Classical Confounding vs Collider-Stratification Bias. *Epidemiology (Cambridge, Mass)*. 2003;14(3):300-6.
6. Galea S, Tracy M. Participation rates in epidemiologic studies. *Annals of epidemiology*. 2007;17(9):643-53.
7. Morton LM, Cahill J, Hartge P. Reporting participation in epidemiologic studies: a survey of practice. *Am J Epidemiol*. 2006;163(3):197-203.
8. Mein G, Johal S, Grant RL, Seale C, Ashcroft R, Tinker A. Predictors of two forms of attrition in a longitudinal health study involving ageing participants: an analysis based on the Whitehall II study. *BMC medical research methodology*. 2012;12:164.
9. Fekete C, Segerer W, Gemperli A, Brinkhof MW, Swi SCISG. Participation rates, response bias and response behaviours in the community survey of the Swiss Spinal Cord Injury Cohort Study (SwiSCI). *BMC medical research methodology*. 2015;15:80.
10. Matthews FE, Chatfield M, Freeman C, McCracken C, Brayne C. Attrition and bias in the MRC cognitive function and ageing study: an epidemiological investigation. *BMC public health*. 2004;4:12.
11. Hayward RD, Krause N. Forms of Attrition in a Longitudinal Study of Religion and Health in Older Adults and Implications for Sample Bias. *Journal of Religion and Health*. 2016;55(1):50-66.

12. Drivsholm T, Eplöv LF, Davidsen M, Jørgensen T, Ibsen H, Hollnagel H, et al. Representativeness in population-based studies: a detailed description of non-response in a Danish cohort study. *Scandinavian journal of public health*. 2006;34(6):623-31.
13. Chatfield MD, Brayne CE, Matthews FE. A systematic literature review of attrition between waves in longitudinal studies in the elderly shows a consistent pattern of dropout between differing studies. *Journal of clinical epidemiology*. 2005;58(1):13-9.
14. Goldberg M, Chastang JF, Zins M, Niedhammer I, Leclerc A. Health problems were the strongest predictors of attrition during follow-up of the GAZEL cohort. *Journal of clinical epidemiology*. 2006;59(11):1213-21.
15. Harald K, Salomaa V, Jousilahti P, Koskinen S, Vartiainen E. Non-participation and mortality in different socioeconomic groups: the FINRISK population surveys in 1972-92. *Journal of epidemiology and community health*. 2007;61(5):449-54.
16. Jousilahti P, Salomaa V, Kuulasmaa K, Niemela M, Vartiainen E. Total and cause specific mortality among participants and non-participants of population based health surveys: a comprehensive follow up of 54 372 Finnish men and women. *Journal of epidemiology and community health*. 2005;59(4):310-5.
17. Stringhini S, Sabia S, Shipley M, Brunner E, Nabi H, Kivimaki M, et al. Association of socioeconomic position with health behaviors and mortality. *Jama*. 2010;303(12):1159-66.
18. Vega S, Benito-Leon J, Bermejo-Pareja F, Medrano MJ, Vega-Valderrama LM, Rodriguez C, et al. Several factors influenced attrition in a population-based elderly cohort: neurological disorders in Central Spain Study. *Journal of clinical epidemiology*. 2010;63(2):215-22.
19. Damen NL, Versteeg H, Serruys PW, van Geuns RJ, van Domburg RT, Pedersen SS, et al. Cardiac patients who completed a longitudinal psychosocial study had a different clinical and psychosocial baseline profile than patients who dropped out prematurely. *European journal of preventive cardiology*. 2015;22(2):196-9.
20. Leening MJ, Heeringa J, Deckers JW, Franco OH, Hofman A, Witteman JC, et al. Healthy volunteer effect and cardiovascular risk. *Epidemiology (Cambridge, Mass)*. 2014;25(3):470-1.

21. Ferrie JE, Kivimäki M, Singh-Manoux A, Shortt A, Martikainen P, Head J, et al. Non-response to baseline, non-response to follow-up and mortality in the Whitehall II cohort. *International Journal of Epidemiology*. 2009;38(3):831-7.
22. Hara M, Sasaki S, Sobue T, Yamamoto S, Tsugane S. Comparison of cause-specific mortality between respondents and nonrespondents in a population-based prospective study: ten-year follow-up of JPHC Study Cohort I. Japan Public Health Center. *Journal of clinical epidemiology*. 2002;55(2):150-6.
23. Candido E, Kurdyak P, Alter DA. Item nonresponse to psychosocial questionnaires was associated with higher mortality after acute myocardial infarction. *Journal of clinical epidemiology*. 2011;64(2):213-22.
24. Delgado-Rodríguez M, Llorca J. Bias. *Journal of epidemiology and community health*. 2004;58(8):635-41.
25. Walker M, Shaper A, Cook D. Non-participation and mortality in a prospective study of cardiovascular disease. *Journal of epidemiology and community health*. 1987;41(4):295-9.
26. Kivimäki M, Batty GD, Pentti J, Shipley MJ, Sipilä PN, Nyberg ST, et al. Association between socioeconomic status and the development of mental and physical health conditions in adulthood: a multi-cohort study. *The Lancet Public Health*. 2020;5(3):e140-e9.
27. Health Do. Alcohol Guidelines Review–Report from the Guidelines Development Group to the UK Chief Medical Officers. Department of Health London; 2016.
28. Wærsted M, Børnick TS, Twisk JWR, Veiersted KB. Simple descriptive missing data indicators in longitudinal studies with attrition, intermittent missing data and a high number of follow-ups. *BMC Research Notes*. 2018;11(1):123.
29. Van Loon AJ, Tijhuis M, Picavet HS, Surtees PG, Ormel J. Survey non-response in the Netherlands: effects on prevalence estimates and associations. *Annals of epidemiology*. 2003;13(2):105-10.
30. Corry NH, Williams CS, Battaglia M, McMaster HS, Stander VA. Assessing and adjusting for non-response in the Millennium Cohort Family Study. *BMC medical research methodology*. 2017;17(1):16.

31. Fernandez-Ballesteros R, Zamarron MD, Diez-Nicolas J, Lopez-Bravo MD, Molina MA, Schettini R. Mortality and refusal in the longitudinal 90+ project. *Archives of gerontology and geriatrics*. 2011;53(2):e203-8.
32. Eaton WW, Anthony JC, Tepper S, Dryman A. Psychopathology and attrition in the epidemiologic catchment area surveys. *Am J Epidemiol*. 1992;135(9):1051-9.
33. Gustavson K, Røysamb E, Borren I. Preventing bias from selective non-response in population-based survey studies: findings from a Monte Carlo simulation study. *BMC medical research methodology*. 2019;19(1):120.
34. Daniel RM, Kenward MG, Cousens SN, De Stavola BL. Using causal diagrams to guide analysis in missing data problems. *Stat Methods Med Res*. 2012;21(3):243-56.
35. Welch CA, Sabia S, Brunner E, Kivimäki M, Shipley MJ. Does pattern mixture modelling reduce bias due to informative attrition compared to fitting a mixed effects model to the available cases or data imputed using multiple imputation?: a simulation study. *BMC medical research methodology*. 2018;18(1):89.
36. Greenland S, Pearl J, Robins JM. *Causal Diagrams for Epidemiologic Research*. *Epidemiology (Cambridge, Mass)*. 1999;10(1):37-48.
37. Daniel RM, De Stavola BL, Cousens SN, Vansteelandt S. Causal mediation analysis with multiple mediators. *Biometrics*. 2015;71(1):1-14.
38. Van Beijsterveldt CE, van Boxtel MP, Bosma H, Houx PJ, Buntinx F, Jolles J. Predictors of attrition in a longitudinal cognitive aging study: the Maastricht Aging Study (MAAS). *Journal of clinical epidemiology*. 2002;55(3):216-23.
39. Batty GD, Shipley M, Tabak A, Singh-Manoux A, Brunner E, Britton A, et al. Generalizability of occupational cohort study findings. *Epidemiology (Cambridge, Mass)*. 2014;25(6):932-3.







Table S1. Association of attrition status at each wave with CVD and Non-CVD mortality up to the subsequent wave. (Analysis 1)

Wave	Response status	No. alive	CVD mortality		Non-CVD mortality	
			No. deaths	SHR (95% CI) ^a	No. deaths	SHR (95% CI) ^a
1	Responders	10 012	12	-	29	-
2	Responders	8024	12	<i>ref.</i>	35	<i>ref.</i>
	Withdrawal/Non-response	1947	9	3.39 (1.35-8.53)	18	2.18 (1.24-3.84)
3	Responders	8647	20	<i>ref.</i>	38	<i>ref.</i>
	Withdrawal/Non-response	1250	3	1.30 (0.38-4.40)	5	0.89 (0.35-2.26)
4	Responders	8462	25	<i>ref.</i>	57	<i>ref.</i>
	Withdrawal/Non-response	1369	9	2.38 (1.11-5.11)	15	1.53 (0.85-2.73)
5	Responders	7723	23	<i>ref.</i>	51	<i>ref.</i>
	Withdrawal/Non-response	2002	9	1.65 (0.75-3.63)	24	1.86 (1.14-3.04)
6	Responders	7231	28	<i>ref.</i>	69	<i>ref.</i>
	Withdrawal/Non-response	2387	15	1.59 (0.84-3.01)	41	1.77 (1.21-2.61)
7	Responders	6855	27	<i>ref.</i>	77	<i>ref.</i>
	Withdrawal/Non-response	2610	22	2.29 (1.29-4.07)	62	2.00 (1.43-2.80)
8	Responders	7054	28	<i>ref.</i>	92	<i>ref.</i>
	Withdrawal/Non-response	2223	16	1.74 (0.95-3.18)	38	1.27 (0.87-1.85)
9	Responders	6655	73	<i>ref.</i>	183	<i>ref.</i>
	Withdrawal/Non-response	2448	55	1.99 (1.40-2.84)	133	1.88 (1.51-2.34)
11	Responders	6213	43	<i>ref.</i>	178	<i>ref.</i>
	Withdrawal/Non-response	2446	36	1.84 (1.15-2.93)	112	1.47 (1.17-1.85)
12 ^b	Responders	5551	21	<i>ref.</i>	64	<i>ref.</i>
	Withdrawal/Non-response	2739	9	0.84 (0.38-1.86)	46	1.27 (0.86-1.86)
<i>P-value for linearity</i>				<i>P=0.11</i>	<i>P=0.61</i>	

^a Adjusted for sex and age

^b Mortality follow-up from wave 12 is up to August 2017

Table S2. Sub-distribution hazard ratios (SHRs) of CVD and Non-CVD mortality from wave 1 to August 2017, by attrition status^a in 10 012 participants (person years as time-scale)

Outcome	Attrition status	No. deaths	SHR (95% CI)			
			<i>Sex and Age</i>		<i>Adjusted for All factors^b</i>	
CVD mortality		495				
	Response	312		<i>ref.</i>		<i>ref.</i>
	Withdrawal/Non-response	183	1.76	(1.45-2.13)	1.46	(1.20-1.79)
Non-CVD mortality		1367				
	Response	873		<i>ref.</i>		<i>ref.</i>
	Withdrawal/Non-response	494	1.54	(1.38-1.73)	1.48	(1.32-1.67)

^a Attrition status is time dependent and varies at each wave of the study

^b Adjusted for sex, age, ethnicity, marital status, employment grade, smoking habit, alcohol drinking, and physical activity

Table S3. Sub-distribution hazard ratios (SHRs) and 95% confidence interval (CIs) of CVD and non-CVD mortality by response status from wave 4 to August 2017 in 8791 participants (Analysis 2)

Outcome	Response status	No. Deaths	SHR (95% CI)							
			Sex and Age		Adjusted for +Demography and health risk behaviours ^b		+General health status ^c			
				<i>p</i> -value ^a		<i>p</i> -value ^a		<i>p</i> -value ^a		
CVD mortality		353								
	Response	258		<i>ref.</i>		<i>ref.</i>		<i>ref.</i>		
	Withdrawal	33	1.28	(0.89-1.84)	0.102	1.14	(0.79-1.65)	0.218	1.21	(0.84-1.75)
	Non-response	62	1.82	(1.37-2.41)		1.49	(1.10-2.01)		1.53	(1.13-2.06)
Non-CVD mortality		1056								
	Response	748		<i>ref.</i>		<i>ref.</i>		<i>ref.</i>		
	Withdrawal	136	1.75	(1.46-2.11)	0.617	1.72	(1.43-2.08)	0.593	1.77	(1.47-2.13)
	Non-response	172	1.65	(1.40-1.95)		1.62	(1.36-1.92)		1.59	(1.34-1.89)

^a P-value of Likelihood Ratio Test between the model with attrition status (response and withdrawal/non-response) and response status (response, withdrawal, non-response)

^b Additionally adjusted for ethnicity, marital status, employment grade, smoking habit, alcohol drinking, and physical activity

^c Additionally adjusted for PCS and MCS from each wave

Table S4. SHRs and 95% CIs of CVD mortality in three models (Analysis 2)

	n=8791	<i>Adjusted for</i>					
		Sex and age		+ Demography and health behaviours		+ Health status	
		SHR	95% CI	SHR	95% CI	SHR	95% CI
Response status							
Response			<i>ref.</i>		<i>ref.</i>		<i>ref.</i>
Withdrawal		1.28	(0.89-1.84)	1.14	(0.79-1.65)	1.21	(0.84-1.75)
Non-response		1.82	(1.37-2.41)	1.49	(1.10-2.01)	1.53	(1.13-2.06)
Sex							
Men			<i>ref.</i>		<i>ref.</i>		<i>ref.</i>
Women		0.78	(0.62-0.98)	0.57	(0.43-0.75)	0.54	(0.40-0.71)
Age in years							
39 and below			<i>ref.</i>		<i>ref.</i>		<i>ref.</i>
40 - 44		1.58	(1.01-2.47)	1.59	(1.01-2.49)	1.50	(0.95-2.36)
45 - 49		3.29	(2.17-5.00)	3.20	(2.09-4.88)	2.79	(1.83-4.25)
50 and over		7.33	(5.03-10.66)	7.20	(4.92-10.54)	6.02	(4.12-8.81)
Ethnicity							
White					<i>ref.</i>		<i>ref.</i>
Non-white				1.49	(1.08-2.05)	1.42	(1.02-1.96)
Marital status							
Married/cohabit					<i>ref.</i>		<i>ref.</i>
Single				1.46	(1.10-1.92)	1.47	(1.12-1.95)
Divorced/widowed				0.96	(0.67-1.39)	0.95	(0.66-1.37)
Employment grade							
High					<i>ref.</i>		<i>ref.</i>
Intermediate				1.07	(0.82-1.40)	1.05	(0.81-1.38)
Low				1.50	(1.05-2.14)	1.47	(1.03-2.11)
Smoking habit							
Never-smoker					<i>ref.</i>		<i>ref.</i>
Ex-smoker				1.11	(0.87-1.42)	1.10	(0.86-1.41)
Current smoker				1.62	(1.23-2.14)	1.54	(1.17-2.03)
Alcohol drinking							
<14 units per week					<i>ref.</i>		<i>ref.</i>
≥14 units per week				0.90	(0.69-1.16)	0.90	(0.70-1.16)
Physical activity							
High					<i>ref.</i>		<i>ref.</i>
Intermediate				0.97	(0.69-1.36)	0.95	(0.68-1.34)
Low				1.34	(1.00-1.78)	1.31	(0.98-1.74)
SF-36: PCS							
Q4 (best)							<i>ref.</i>
Q3						1.61	(1.01-2.35)
Q2						1.42	(0.97-2.09)
Q1 (worst)						2.39	(1.68-3.40)
SF-36: MCS							
Q4 (best)							<i>ref.</i>
Q3						0.84	(0.63-1.11)
Q2						0.72	(0.53-0.96)
Q1 (worst)						0.74	(0.56-0.98)

Table S5. SHRs and 95% CIs of non-CVD mortality in three models (Analysis 2)

	n=8791	Sex and age		<i>Adjusted for</i> + Demography and health behaviours		+ Health status	
		SHR	95% CI	SHR	95% CI	SHR	95% CI
Response status							
Response		<i>ref.</i>		<i>ref.</i>		<i>ref.</i>	
Withdrawal		1.75	(1.46-2.11)	1.72	(1.43-2.08)	1.77	(1.47-2.13)
Non-response		1.65	(1.40-1.95)	1.62	(1.36-1.92)	1.59	(1.34-1.89)
Sex							
Men		<i>ref.</i>		<i>ref.</i>		<i>ref.</i>	
Women		0.94	(0.83-1.07)	0.95	(0.81-1.11)	0.90	(0.76-1.05)
Age in years							
39 and below		<i>ref.</i>		<i>ref.</i>		<i>ref.</i>	
40 - 44		1.30	(1.04-1.63)	1.30	(1.04-1.64)	1.29	(1.03-1.63)
45 - 49		2.25	(1.82-2.79)	2.33	(1.88-2.89)	2.22	(1.78-2.77)
50 and over		4.56	(3.78-5.50)	4.76	(3.93-5.77)	4.45	(3.65-5.42)
Ethnicity							
White				<i>ref.</i>		<i>ref.</i>	
Non-white				0.75	(0.60-0.94)	0.69	(0.55-0.87)
Marital status							
Married/cohabit				<i>ref.</i>		<i>ref.</i>	
Single				1.00	(0.84-1.20)	0.97	(0.82-1.16)
Divorced/widowed				1.05	(0.86-1.28)	1.02	(0.84-1.24)
Employment grade							
High				<i>ref.</i>		<i>ref.</i>	
Intermediate				1.02	(0.88-1.17)	0.99	(0.86-1.15)
Low				0.89	(0.73-1.09)	0.83	(0.68-1.02)
Smoking habit							
Never-smoker				<i>ref.</i>		<i>ref.</i>	
Ex-smoker				1.09	(0.94-1.25)	1.06	(0.92-1.22)
Current smoker				2.04	(1.75-2.37)	1.91	(1.64-2.23)
Alcohol drinking							
<14 units per week				<i>ref.</i>		<i>ref.</i>	
≥14 units per week				1.10	(0.96-1.26)	1.10	(0.96-1.26)
Physical activity							
High				<i>ref.</i>		<i>ref.</i>	
Intermediate				0.81	(0.68-0.97)	0.80	(0.67-0.96)
Low				0.96	(0.83-1.12)	0.92	(0.79-1.07)
SF-36: PCS							
Q4 (best)						<i>ref.</i>	
Q3						1.20	(0.97-1.49)
Q2						1.42	(1.16-1.74)
Q1 (worst)						2.04	(1.69-2.46)
SF-36: MCS							
Q4 (best)						<i>ref.</i>	
Q3						1.01	(0.85-1.20)
Q2						1.18	(0.99-1.39)
Q1 (worst)						1.32	(1.12-1.56)